Newsfeed

Discovery sheds light on how changes in lungs can hurt the heart
A team of UW-Madison researchers has discovered important biomechanical changes in human arteries that could increase understanding of how pulmonary hypertension leads to heart failure. Photo: Naomi Chesler Naomi Chesler The team, led by Naomi Chesler, an associate professor of biomedical engineering, released its findings in a paper published in the journal PLOS ONE on Nov. 6, 2013. The disease pulmonary hypertension causes high blood …
Pulmonary Hypertension Associated With Scurvy and Vitamin Deficiencies in an Autistic Child
Restricted dietary intake is common among children with behavioral issues. Here we report a case of a severely autistic child who presented initially with limp but who soon developed cough, tachypnea, hypoxia, and tachycardia. An echocardiogram revealed evidence of pulmonary hypertension (PH) with severely dilated right ventricle and elevated right-sided pressures. The etiology of his PH was unclear but further laboratory evaluation demonstrated …
Angina Drug May Work in HF
CHICAGO -- The anti-angina agent ranolazine (Ranexa) may work in a condition for which there are few options in terms of drug therapy: pulmonary hypertension (PH) tied to heart failure with preserved ejection fraction (HF-pEF), researchers found. In a small pilot study that lacked a control group, the drug was tied to a 41% decrease from baseline in mean pulmonary arterial pressure over 6 months, Harrison Farber, MD, of Boston University Medic…
Antibody therapy reverses fatal lung disease
U. SHEFFIELD (UK) — Scientists have found an antibody treatment that not only stops a fatal lung disease from getting worse, but also reverses the condition in mice and rats. The breakthrough could pave the way for new treatments for patients with pulmonary arterial hypertension (PAH), which often affects young people and more commonly women. The findings are detailed in the Journal of Experimental Medicine. The condition is caused by chang…
Both Sides Now: Raising Awareness and Improving Treatment of Pulmonary Hypertension
Few health challenges are as well-publicized as high blood pressure, a topic that has become all too familiar, appearing everywhere from the daily news to medical conferences. And being so familiar, it is easy to overlook the fact that most of this attention has been devoted to a problem that stems from just one side of the heart. In fact, talk of high blood pressure usually refers to systemic hypertension, a condition that depends on how well t…
Seattle boy again campaigning for health care changes
by CHRIS DANIELS / KING 5 News KREM.com Posted on October 1, 2013 at 10:23 AM SEATTLE - Three years ago, he thrust himself into the health care reform debate. The now 14-year-old Marcelas Owens is ready to do it again. He says the discussion in Congress has caused him to think about the legislation, which he pushed for years ago. “It’s going to help a lot of people,” said the now high school student Monday night, “a lot of people will be…
Galectin-3 strong prognostic marker in patients with pulmonary hypertension
ORLANDO, Fla. — Patients with pulmonary hypertension and elevated galectin-3 were more likely to have a higher mortality rate at 4 years compared with patients with lower levels of the biomarker, according to data presented at the Annual Scientific Meeting of the Heart Failure Society of America. Previous research has linked high levels of galectin-3 to increased mortality in HF. However, the association had not been studied in patients with p…
Bayer receives approval for Adempas® as first drug to treat rare heart and lung disease
Adempas® (riociguat) offers new hope for patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) Adempas® is now available in Canada as the first and only drug indicated to manage the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)1,2 TORONTO, Sept. 23, 2013 /CNW/ - Bayer Inc. announced today the Health Canada approval of Adempas® (riociguat). Adempas® is the first drug indicated to manage the treatment …
Actelion Pharmaceuticals Canada Introduces CARIPUL® (epoprostenol) For Injection, A Treatment for Pulmonary Arterial Hypertension
Actelion Pharmaceuticals Canada Inc. announced today that CARIPUL® (epoprostenol) for Injection is now available in Canada. CARIPUL® is a prescription medication indicated for the long-term intravenous treatment of primary pulmonary hypertension (or idiopathic pulmonary arterial hypertension), and secondary pulmonary hypertension due to scleroderma spectrum of diseases in NYHA functional Class III and Class IV patients who did not respond ade…
Cuba grad awaiting double lung transplant
Imagine not being able to laugh or cry without feeling as if you were suffocating. Imagine going from an active lifestyle to not being able to walk even a short distance without losing your breath. Imagine being on oxygen 24 hours a day. Imagine your heart being six times larger than average and covering three-fourths of a lung. Imagine if the only chance you had to live was to have a double lung transplant that costs nearly $800,000. And no…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png